H.C. Wainwright raised the firm’s price target on Structure Therapeutics (GPCR) to $114 from $90 and keeps a Buy rating on the shares. The firm believes the 44-week ACCESS II data, expected in Q1, could be the most significant near-term catalyst for “crystallizing” Structure’s takeover interest.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GPCR:
- Structure Therapeutics price target lowered to $113 from $120 at Citizens
- Buy Rating on Structure Therapeutics: Strong Phase II Data and Upcoming Late‑Stage Catalysts Support Upside for Oral GLP‑1 Aleniglipron
- Midday Fly By: Warsh nominated for Fed chair, Apple reports Q1 beat
- Structure Therapeutics emerges as top M&A target for big pharma, Axios says
- Structure Therapeutics price target raised to $105 from $65 at JPMorgan